Ticagrelor-induced Sweet Syndrome: an unusual dermatologic complication after percutaneous coronary intervention.

A 73-year-old male underwent cardiac catheterization and received two Everolimus drug eluting stents for 80 % stenotic lesions in the left anterior descending and right coronary arteries. He was discharged on aspirin and ticagrelor. He started noticing progressive multiple painful hemorrhagic bullae on the palms of both hands. Biopsy showed lesions consistent with Sweet Syndrome (SS). He was started on steroids and ticagrelor was switched to Clopidogrel with improvement in rash without recurrence. SS is an inflammatory disorder characterized by the abrupt appearance of painful, edematous, and erythematous lesions on the skin. This is the first reported case of SS associated with ticagrelor.